Time to first transfusion in lower-risk patients with myelodysplastic neoplasia (MDS) is another prognostic factor of survival

Leuk Lymphoma. 2023 Jul-Aug;64(8):1476-1479. doi: 10.1080/10428194.2023.2214649. Epub 2023 May 31.

Authors

Hans Tilman Steinmetz¹, J Toczek-Thiel¹, J Lipke², R Liersch³, A Sauer⁴, H Tesch⁵, J Heßling⁶, U Totzke⁷, S Schmitz¹

Affiliations

¹ Outpatient Clinics for Hematology and Oncology, Cologne, Germany.
² Outpatient Clinics for Hematology and Oncology, Dortmund, Germany.
³ Outpatient Clinics for Hematology and Oncology, Münster, Germany.
⁴ Outpatient Clinics for Hematology and Oncology, Potsdam, Germany.
⁵ Outpatient Clinics for Hematology and Oncology, Frankfurt/Main, Germany.
⁶ Outpatient Clinics for Hematology and Oncology, Berlin, Germany.
⁷ TDS, Basel, Switzerland.

PMID: 37254711
DOI: 10.1080/10428194.2023.2214649

No abstract available

Publication types

Letter

MeSH terms

Blood Transfusion
Humans
Myelodysplastic Syndromes* / diagnosis
Myelodysplastic Syndromes* / therapy
Neoplasms*
Prognosis
Risk